Met Life Investment Management, LLC Black Diamond Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 22,286 shares of BDTX stock, worth $61,063. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,286
Previous 9,729
129.07%
Holding current value
$61,063
Previous $45,000
113.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding BDTX
# of Institutions
117Shares Held
48.8MCall Options Held
1.84MPut Options Held
1.93M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$29.4 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$23.3 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$13.8 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$12.2 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.81 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $99.6M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...